II期临床-话题@MedSci

#II期临床#

478篇内容 | 2511人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1524567, encodeId=b8e4152456e54, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=诺华白血病药物Arzerra III期临床显著改善复发性CLL无进展生存期, objectType=article, longId=52073, objectId=0df1520e32c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0df1520e32c, replyNumber=0, likeNumber=30, createdTime=2015-06-17, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0df1520e32c, moduleTitle=诺华白血病药物Arzerra III期临床显著改善复发性CLL无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0df1520e32c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524566, encodeId=abb015245663b, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=ASCO 2015：III期临床研究：康复新液对鼻咽癌患者放化疗引起的口腔和上消化道黏膜炎疗效, objectType=article, longId=51623, objectId=b8435162302, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8435162302, replyNumber=0, likeNumber=30, createdTime=2015-06-05, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8435162302, moduleTitle=ASCO 2015：III期临床研究：康复新液对鼻咽癌患者放化疗引起的口腔和上消化道黏膜炎疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8435162302)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524565, encodeId=ce75152456591, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Lancet Oncol：帕唑帕尼加每周紫杉醇用于晚期卵巢癌的II期临床研究, objectType=article, longId=50354, objectId=7a1c50354b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a1c50354b4, replyNumber=0, likeNumber=52, createdTime=2015-05-08, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a1c50354b4, moduleTitle=Lancet Oncol：帕唑帕尼加每周紫杉醇用于晚期卵巢癌的II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a1c50354b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524564, encodeId=8f201524564e0, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Clin Cancer Res：Palbociclib 对Rb+晚期乳腺癌的II期临床研究, objectType=article, longId=48832, objectId=5c1248832b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c1248832b6, replyNumber=0, likeNumber=69, createdTime=2015-04-02, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c1248832b6, moduleTitle=Clin Cancer Res：Palbociclib 对Rb+晚期乳腺癌的II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c1248832b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524563, encodeId=f033152456362, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Ann Oncol：MEK抑制剂trametinib对KRAS突变的非小细胞肺癌的II期临床研究, objectType=article, longId=47689, objectId=936f4e689f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=936f4e689f6, replyNumber=0, likeNumber=36, createdTime=2015-03-05, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=936f4e689f6, moduleTitle=Ann Oncol：MEK抑制剂trametinib对KRAS突变的非小细胞肺癌的II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=936f4e689f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524562, encodeId=5f43152456240, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=诺华眼科新药RTH258 II期临床疗效媲美拜耳Eylea, objectType=article, longId=47665, objectId=3c6b4e665fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c6b4e665fd, replyNumber=0, likeNumber=55, createdTime=2015-03-05, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c6b4e665fd, moduleTitle=诺华眼科新药RTH258 II期临床疗效媲美拜耳Eylea, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c6b4e665fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524561, encodeId=039315245612c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=安进甲旁亢新药AMG416 III期临床实现三连胜，头对头研究轻松击败Sensipar, objectType=article, longId=47489, objectId=e2e24e48911, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e2e24e48911, replyNumber=0, likeNumber=52, createdTime=2015-03-01, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e2e24e48911, moduleTitle=安进甲旁亢新药AMG416 III期临床实现三连胜，头对头研究轻松击败Sensipar, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e2e24e48911)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524560, encodeId=aed4152456044, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Clin Cancer Res：尼罗替尼对KIT突变的黑色素瘤的II期临床研究, objectType=article, longId=47422, objectId=08b34e422c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08b34e422c6, replyNumber=0, likeNumber=83, createdTime=2015-02-26, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08b34e422c6, moduleTitle=Clin Cancer Res：尼罗替尼对KIT突变的黑色素瘤的II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08b34e422c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524559, encodeId=f4ff152455913, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Lancet Oncol：舒尼替尼治疗化疗难治性胸腺瘤和胸腺癌---项开放的II期临床研究, objectType=article, longId=46140, objectId=3e594614037, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e594614037, replyNumber=0, likeNumber=58, createdTime=2015-01-28, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e594614037, moduleTitle=Lancet Oncol：舒尼替尼治疗化疗难治性胸腺瘤和胸腺癌---项开放的II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e594614037)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524558, encodeId=3dbc1524558c7, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Lancet子刊：2型糖尿病新药trelagliptin III期临床试验结果乐观, objectType=article, longId=45947, objectId=66654594e34, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66654594e34, replyNumber=0, likeNumber=55, createdTime=2015-01-23, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66654594e34, moduleTitle=Lancet子刊：2型糖尿病新药trelagliptin III期临床试验结果乐观, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66654594e34)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524557, encodeId=0ed3152455eab, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Lancet Oncology：III期临床试验显示非小细胞肺癌治疗现有方案仍最理想, objectType=article, longId=45906, objectId=c85f4590698, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c85f4590698, replyNumber=0, likeNumber=54, createdTime=2015-01-23, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c85f4590698, moduleTitle=Lancet Oncology：III期临床试验显示非小细胞肺癌治疗现有方案仍最理想, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c85f4590698)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524556, encodeId=a42115245567f, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=NGGZ：哌加他尼钠针对糖尿病黄斑水肿患者在日本进行III期临床研究, objectType=article, longId=43449, objectId=ff854344901, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff854344901, replyNumber=0, likeNumber=59, createdTime=2014-12-01, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff854344901, moduleTitle=NGGZ：哌加他尼钠针对糖尿病黄斑水肿患者在日本进行III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff854344901)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524555, encodeId=f0a4152455530, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=诺华单抗secukinumab强直性脊柱炎III期临床大获成功, objectType=article, longId=41756, objectId=a38e41e563a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a38e41e563a, replyNumber=0, likeNumber=77, createdTime=2014-10-29, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a38e41e563a, moduleTitle=诺华单抗secukinumab强直性脊柱炎III期临床大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a38e41e563a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524554, encodeId=e5c8152455496, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=汤森路透：五个进入II期临床试验的更具前景药物品种, objectType=article, longId=41019, objectId=db344101960, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db344101960, replyNumber=0, likeNumber=72, createdTime=2014-10-11, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db344101960, moduleTitle=汤森路透：五个进入II期临床试验的更具前景药物品种, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db344101960)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524553, encodeId=780b15245532b, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=汤森路透：五个进入III期临床试验的更具前景药物品种, objectType=article, longId=40850, objectId=966c408506a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=966c408506a, replyNumber=0, likeNumber=66, createdTime=2014-10-02, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=966c408506a, moduleTitle=汤森路透：五个进入III期临床试验的更具前景药物品种, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=966c408506a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524551, encodeId=bfc51524551de, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=III期临床：新药研发的“麦城”, objectType=article, longId=38551, objectId=8f7338551d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f7338551d9, replyNumber=0, likeNumber=62, createdTime=2014-08-03, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f7338551d9, moduleTitle=III期临床：新药研发的“麦城”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f7338551d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524552, encodeId=f7b2152455251, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=默克雪兰诺启动抗PD-L1免疫疗法II期临床研究, objectType=article, longId=38553, objectId=67103855384, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67103855384, replyNumber=0, likeNumber=64, createdTime=2014-08-03, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67103855384, moduleTitle=默克雪兰诺启动抗PD-L1免疫疗法II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=67103855384)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524550, encodeId=094f152455099, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=COPD三联疗法（FF/UMEC/VI)III期临床研究启动（IMPACT试验）, objectType=article, longId=38150, objectId=2fcf38150b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fcf38150b2, replyNumber=0, likeNumber=71, createdTime=2014-07-25, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fcf38150b2, moduleTitle=COPD三联疗法（FF/UMEC/VI)III期临床研究启动（IMPACT试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fcf38150b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524548, encodeId=35cc152454811, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Gynecol Oncol：吉非替尼联合S-1与卡铂一线治疗发生表皮生长因子受体突变的晚期非小细胞肺癌患者的II期临床试验, objectType=article, longId=37047, objectId=6eb73e0471c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6eb73e0471c, replyNumber=0, likeNumber=58, createdTime=2014-06-27, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6eb73e0471c, moduleTitle=Gynecol Oncol：吉非替尼联合S-1与卡铂一线治疗发生表皮生长因子受体突变的晚期非小细胞肺癌患者的II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6eb73e0471c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524549, encodeId=158f152454964, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Lancet Oncol：S-1联合奥沙利铂与卡培他滨联合奥沙利铂一线治疗转移性结直肠癌患者：一项III期临床试验的全新结果, objectType=article, longId=37049, objectId=a8b93e049a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8b93e049a1, replyNumber=0, likeNumber=30, createdTime=2014-06-27, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8b93e049a1, moduleTitle=Lancet Oncol：S-1联合奥沙利铂与卡培他滨联合奥沙利铂一线治疗转移性结直肠癌患者：一项III期临床试验的全新结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8b93e049a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期临床

2020-05-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

诺华白血病药物Arzerra III期临床显著改善复发性CLL无进展生存期

2015-06-17

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

ASCO 2015：III期临床研究：康复新液对鼻咽癌患者放化疗引起的口腔和上消化道黏膜炎疗效

2015-06-05

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Lancet Oncol：帕唑帕尼加每周紫杉醇用于晚期卵巢癌的II期临床研究

2015-05-08

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Clin Cancer Res：Palbociclib 对Rb+晚期乳腺癌的II期临床研究

2015-04-02

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Ann Oncol：MEK抑制剂trametinib对KRAS突变的非小细胞肺癌的II期临床研究

2015-03-05

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

诺华眼科新药RTH258 II期临床疗效媲美拜耳Eylea

2015-03-05

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

安进甲旁亢新药AMG416 III期临床实现三连胜，头对头研究轻松击败Sensipar

2015-03-01

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Clin Cancer Res：尼罗替尼对KIT突变的黑色素瘤的II期临床研究

2015-02-26

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Lancet Oncol：舒尼替尼治疗化疗难治性胸腺瘤和胸腺癌---项开放的II期临床研究

2015-01-28

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Lancet子刊：2型糖尿病新药trelagliptin III期临床试验结果乐观

2015-01-23

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Lancet Oncology：III期临床试验显示非小细胞肺癌治疗现有方案仍最理想

2015-01-23

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

NGGZ：哌加他尼钠针对糖尿病黄斑水肿患者在日本进行III期临床研究

2014-12-01

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

诺华单抗secukinumab强直性脊柱炎III期临床大获成功

2014-10-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

汤森路透：五个进入II期临床试验的更具前景药物品种

2014-10-11

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

汤森路透：五个进入III期临床试验的更具前景药物品种

2014-10-02

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

III期临床：新药研发的“麦城”

2014-08-03

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

默克雪兰诺启动抗PD-L1免疫疗法II期临床研究

2014-08-03

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

COPD三联疗法（FF/UMEC/VI)III期临床研究启动（IMPACT试验）

2014-07-25

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Gynecol Oncol：吉非替尼联合S-1与卡铂一线治疗发生表皮生长因子受体突变的晚期非小细胞肺癌患者的II期临床试验

2014-06-27

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Lancet Oncol：S-1联合奥沙利铂与卡培他滨联合奥沙利铂一线治疗转移性结直肠癌患者：一项III期临床试验的全新结果

2014-06-27

科室
- - 订阅+
  - 更多科室
工具
服务